Slope of change in HbA<sub>1c</sub> from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetes.

Endocrinol Diabetes Metab · 2018 · PMC6354821 · PMID 30815552

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

of borderline significanceP = .07so close (0.05 < p ≤ 0.1)

The slopes were steeper for empagliflozin 25 mg compared with glimepiride, reaching significance at week 52 ( P < .001), and were of borderline significance at week 104 ( P = .07).

also in 2,624 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.